Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR TherapeuticsTM, a new class of drugs for the treatment of multiple diseases and disorders of the nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.
We have a robust clinical-stage product pipeline that includes multiple mid-stage product candidates, as well as preclinical programs. Our most advanced product candidates are in development for residual symptoms in schizophrenia, attention deficit/hyperactivity disorder (inattentive-predominant), Alzheimer’s disease and inflammatory disorders.
Targacept is located in Winston-Salem, North Carolina.
Targacept has several product candidates in clinical development.
View our pipeline to learn more.
On May 2, 2011, The Scientist magazine announced the winners of its 9th annual "Best Places to Work in Industry" survey... more.....